Poseida Therapeutics, Inc.

NASDAQ:PSTX

3.07 (USD) • At close September 13, 2024
Bedrijfsnaam Poseida Therapeutics, Inc.
Symbool PSTX
Munteenheid USD
Prijs 3.07
Beurswaarde 298,201,073
Dividendpercentage 0%
52-weken bereik 1.83 - 4.27
Industrie Biotechnology
Sector Healthcare
CEO Mr. Mark J. Gergen J.D.
Website https://www.poseida.com

An error occurred while fetching data.

Over Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).

Vergelijkbare Aandelen

Olema Pharmaceuticals, Inc. logo

Olema Pharmaceuticals, Inc.

OLMA

12.7 USD

MDxHealth SA logo

MDxHealth SA

MDXH

2.375 USD

MediciNova, Inc. logo

MediciNova, Inc.

MNOV

1.82 USD

Shattuck Labs, Inc. logo

Shattuck Labs, Inc.

STTK

3.81 USD

OncoCyte Corporation logo

OncoCyte Corporation

OCX

3.08 USD

ImmunoPrecise Antibodies Ltd. logo

ImmunoPrecise Antibodies Ltd.

IPA

0.67 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)